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Combined Hypothermic and 
Normothermic Machine Perfusion 
Improves Functional Recovery of 
Extended Criteria Donor Livers
Yuri L. Boteon,1,3 Richard W. Laing,1,3* Andrea Schlegel,1* Lorraine Wallace,3 Amanda Smith,1 
Joseph Attard,1 Ricky H. Bhogal,1,3 Desley A. H. Neil,2 Stefan Hübscher,2  
M. Thamara P. R. Perera,1 Darius F. Mirza,1,3 Simon C. Afford,3* and Hynek Mergental1,3*
1 Liver Unit; 2 Department of Pathology, Queen Elizabeth Hospital, University Hospitals Birmingham National Health Service 
Foundation Trust, Birmingham, United Kingdom; and 3 National Institute for Health Research, Birmingham Biomedical 
Research Centre, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of 
Birmingham, Birmingham, United Kingdom
Hypothermic oxygenated perfusion (HOPE) and normothermic perfusion are seen as distinct techniques of ex situ machine 
perfusion of the liver. We aimed to demonstrate the feasibility of combining both techniques and whether it would improve 
functional parameters of donor livers into transplant standards. Ten discarded human donor livers had either 6 hours of nor-
mothermic perfusion (n = 5) or 2 hours of HOPE followed by 4 hours of normothermic perfusion (n = 5). Liver function was 
assessed according to our viability criteria; markers of tissue injury and hepatic metabolic activity were compared between 
groups. Donor characteristics were comparable. During the hypothermic perfusion phase, livers down-regulated mitochondrial 
respiration (oxygen uptake, P = 0.04; partial pressure of carbon dioxide perfusate, P = 0.04) and increased adenosine triphos-
phate levels 1.8-fold. Following normothermic perfusion, those organs achieved lower tissue expression of markers of oxidative 
injury (4-hydroxynonenal, P = 0.008; CD14 expression, P = 0.008) and inflammation (CD11b, P = 0.02; vascular cell adhe-
sion molecule 1, P = 0.05) compared with livers that had normothermic perfusion alone. All livers in the combined group 
achieved viability criteria, whereas 40% (2/5) in the normothermic group failed (P = 0.22). In conclusion, this study suggests 
that a combined protocol of hypothermic oxygenated and normothermic perfusions might attenuate oxidative stress, tissue 
inflammation, and improve metabolic recovery of the highest-risk donor livers compared with normothermic perfusion alone.
Liver Transplantation 24 1699‒1715 2018 AASLD.
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SEE EDITORIAL ON PAGE 1647
The rising incidence of liver disease, in combina-
tion with changes in organ donor demographics, has 
increased reliance on extended criteria donor (ECD) 
livers for transplantation globally.(1,2) Although these 
organs have inferior outcomes compared with stan-
dard criteria livers, their use is deemed necessary to 
control the wait-list mortality.(3-5) Current utilization 
of ECD livers remains relatively low mainly when 
risk factors concur. For example, in the United 
Kingdom, 17% of the procured livers are currently not 
transplanted.(6)
Ex situ machine perfusion is a novel preservation 
method developed to protect organs from the detri-
mental effects of ischemia during static cold storage 
BOTEON ET AL.
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(SCS). Potential beneficial protective mechanisms 
of machine perfusion have been demonstrated for 
both hypothermic and normothermic perfusion 
techniques during preclinical experiments and pilot 
clinical studies.(7-9)
Hypothermic oxygenated perfusion (HOPE) may 
permit mitochondrial functional recovery, increas-
ing cellular adenosine triphosphate (ATP) levels, 
and mitigate the injury to the tissue that occurs 
during rewarming.(9) Although there is mounting 
evidence of the protective effect of HOPE on the 
liver graft quality, evidence regarding its value in 
viability testing is still under investigation. Previous 
studies reported a correlation between perfusate 
transaminases content and its posttransplant levels, 
suggesting that hepatocellular injury could poten-
tially be assessed also outside of normothermia.(10,11) 
Normothermic machine perfusion (NMP) of the 
liver enables metabolism at physiological tempera-
ture and, therefore, facilitates functional assess-
ment.(12) Several groups including our own have 
demonstrated that viability assessment by NMP 
can be used to select transplantable livers from the 
pool of currently discarded organs.(12,13) There are 
no convincing data, however, to show that NMP 
improves the quality of ECD organs injured by cold 
ischemia storage. The key benefit of NMP might 
be in preventing any deterioration of liver quality 
from the time of commencing the perfusion and by 
providing a snapshot of the organ injury occurred, 
with the opportunity to assess multiple functional 
parameters.
Data from our research on NMP perfusions showed 
that a proportion of poor-quality livers exposed to pro-
longed cold storage do not recover their function and 
fail our viability criteria (unpublished observations). 
Although hypothermic perfusion and normothermic 
perfusion were developed as distinct strategies, we 
hypothesized that HOPE might be seen as a beneficial 
therapeutic intervention by restoring liver metabolism 
prior to a period of normothermic perfusion, which 
permits liver viability testing. The present study aimed 
to assess the feasibility of a protocol combining HOPE 
with NMP and to investigate its potential benefits over 
NMP alone.
Patients and Methods
sTUDY DEsIGN
The study was designed to compare 2 perfusion strat-
egies to restore function of high-risk ECD livers, fol-
lowing a period of SCS, within the certified 6-hour 
timeframe allowed by the used perfusion device.
The study endpoints were evaluation of hepa-
tocellular injury and liver function assessment. 
Ten discarded human donor livers were consecu-
tively assigned to 2 study groups, each consisting 
of 5 organs and all perfused for 6 hours. Livers in 
1 group were exposed to normothermic perfusion 
alone (NMP group, performed first), while the other 
group underwent 2 hours of HOPE, followed by 4 
hours of normothermic perfusion (HOPE + NMP 
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group). Figure 1 shows the study design and sampling 
protocol.
sOURCE OF DIsCARDED HUMAN 
LIvERs
All included livers were procured with the intention 
of transplantation according to the National Organ 
Retrieval Service standards. The organs were declined 
for clinical use by all the UK liver transplant centers and 
subsequently offered for research purposes. The livers 
were preserved in University of Wisconsin fluid under 
standard clinical practice of SCS prior to commenc-
ing perfusion. The study protocol was approved by the 
appropriate institutional review committee. Ethical 
approval for the study was obtained by the London-
Surrey Borders National Research Ethics Service and 
the National Health Service Blood and Transplant 
Ethics Committee (references 13/LO/1928 and 06/
Q702/61, respectively).
LIvER pERFUsION pROCEDURE
The liver preparation for the perfusion was carried out 
using a standard clinical back-table procedure as de-
scribed elsewhere.(14) The cystic duct was ligated, and 
the celiac trunk, portal vein (PV), and bile duct were 
cannulated with a 12-Fr biliary drain. Before commenc-
ing machine perfusion, the liver was flushed with 2 L of 
5% glucose solution and placed into the device reservoir. 
Then the cannulas were connected to the perfusion cir-
cuits. The Liver Assist device (Organ Assist, Groningen, 
the Netherlands) provides dual perfusion of the hepatic 
artery (HA) and PV in a semiclosed circuit by 2 rotary 
pumps to produce pulsatile and nonpulsatile flows, re-
spectively.(15) The perfusate temperature and perfusion 
pressures were set by the operator, and the measured flow 
rates and calculated resistances, shown on the device’s 
display in real time, were recorded every 30 minutes. 
Oxygen was supplied via a Sechrist air/oxygen blender 
(S3500CP-G, Inspiration Healthcare, Ltd., Leicester, 
FIG. 1. Study design. Discarded human livers were subjected to our routine organ procurement procedure and then cold f lushed and 
cold stored. The organs were allocated randomly into 2 experimental groups of end-ischemic machine perfusion. The NMP group was 
subjected to 6 hours NMP at 37°C, and the HOPE + NMP group was subjected to 2 hours of HOPE followed by 4 hours of NMP. 
Menghini and wedge biopsies were collected at time 0 and 6 hours (**) and immediately fixed in formalin or snap-frozen in liquid 
nitrogen. The HOPE + NMP group had an extra liver biopsy taken at 2 hours. Blood gas analysis was carried out, and perfusate was 
sampled at 30-minute time intervals throughout (*). In addition, bile was collected and weighed at a time of 4 and 6 hours (#).
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United Kingdom) with the fraction of inspired oxygen 
and air flow adjusted as specified below.
HYpOTHERMIC OXYGENATED 
pERFUsION
HOPE was performed via PV only, using 3 L of Belzer 
MPS University of Wisconsin Machine Perfusion 
Solution (Bridge to Life, Ltd., EU) with the tempera-
ture set at 10°C. The target f low was 0.1 mL/minute/g 
of liver with a maximum pressure of 3 mm Hg. The 
target oxygen perfusate pressure was 80-100 kPa. 
After 2 hours of HOPE, the perfusion was stopped 
and the liver temporarily placed on ice. The system 
was then drained and subsequently refilled with the 
NMP perfusion solution. The HA and common bile 
duct were cannulated and then the normothermic per-
fusion commenced. The perfusate exchange, from the 
end of HOPE to the start of NMP, took an average of 
20 minutes.
NORMOTHERMIC MACHINE 
pERFUsION
The perfusion f luid for NMP consisted of 1000 mL 
(4 units) of an acellular, polymerized bovine hemo-
globin-based oxygen carrier Hemopure (Hemoglobin 
Oxygen Therapeutics LLC, Cambridge, MA) com-
plemented with human albumin solution and addi-
tional supplements as described in Supporting Table 1. 
For superior oxygen delivery, rheological characteris-
tics, and research logistics, this solution became our 
preferred perfusate.(16)
The target flow was 0.25 mL/minute/g liver tissue 
on the arterial side and 0.75 mL/minute/g liver tissue 
in the venous circuit. To achieve these flows, perfusion 
pressures on the device were adjusted between 30-50 
mm Hg (mean pressure) on the arterial side and 8-10 
mm Hg on the PV. The temperature was initially set 
at 20°C and increased incrementally to 37°C within 30 
minutes of starting NMP. The target perfusate oxygen 
pressure was 40 kPa.
sAMpLEs AND DATA 
COLLECTION pROTOCOL
Liver biopsies were taken before commencing the 
perfusion (t = 0), after finishing the HOPE perfu-
sion (t = 2 hours), and on completion of NMP (t = 
6 hours; Fig. 1). Biopsies were immediately either 
placed in formalin or snap-frozen in liquid nitrogen 
for subsequent analysis. The biopsy at the end of the 
HOPE phase was used for ATP assessment only, and 
all other analyses were done on biopsies from the be-
ginning and end of the perfusion. The perfusate was 
sampled every 30 minutes throughout the perfusion 
in both groups and analyzed immediately for blood 
gases or snap-frozen and stored for later analyses. 
Bile produced during the perfusion was collected via 
a 12-Fr silicon tube inserted into the common bile 
duct and weighed at 4 and 6 hours of machine perfu-
sion in both groups. The density of bile was consid-
ered 1 g/mL, and this was normalized for liver mass.
AssEssMENT OF LIvER 
FUNCTION
Arterial and venous perfusates were assessed using a 
Cobas b 221 (Roche Diagnostics, Indianapolis, IN) 
point-of-care system blood gas analyzer. Parameters in-
cluded partial pressure of oxygen and partial pressure of 
carbon dioxide (PCO2), pH, base excess, bicarbonate, O2 
saturation, hemoglobin, hematocrit, sodium, potassium, 
chloride, calcium, glucose, and lactate concentrations.
Oxygen uptake was calculated during the HOPE per-
fusion as the difference between the oxygen inflow minus 
the outflow in kPa, corrected by liver weight and liters 
of perfusate. During NMP, the oxygen consumption 
was calculated from the difference between the oxygen 
content after the oxygenator and the return into the oxy-
genator in the venous circuit. Oxygen content was calcu-
lated as the sum of the free dissolved oxygen fraction to 
the hemoglobin-bound oxygen fraction (equation in the 
Supporting Methods) as described elsewhere.(17)
The viability of the organ was assessed at the end 
of the perfusion by our unit’s clinical criteria, based on 
perfusate lactate levels falling to concentrations of <2.5 
mmol/L within 6 hours, in combination with evidence 
of bile production, stable vascular flows, and homoge-
neous parenchymal perfusion.(12)
HIsTOpATHOLOGICAL 
AssEssMENT OF HEpATOCYTE 
INJURY
Menghini needle and wedge biopsies obtained prior 
to perfusion and at the end were fixed in formalin, 
processed, and embedded in paraffin. Thereafter, 
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4-μm sections were cut and stained with hema-
toxylin-eosin and periodic acid–Schiff (PAS). 
Hematoxylin-eosin sections were semiquantita-
tively graded for ischemic-type coagulative necrosis, 
large- and small-droplet macrovesicular steatosis, 
and preexisting acute or chronic liver disease. The 
PAS-stained sections were scored for percentage of 
hepatocytes depleted of glycogen, and the variation 
between the beginning and the end of the perfusion 
compared across groups. Histological assessment 
was conducted by an experienced liver transplant pa-
thologist without prior knowledge of the designated 
perfusion category or outcome.
IMMUNOHIsTOCHEMICAL 
AssEssMENT OF OXIDATIvE 
sTREss AND TIssUE 
INFLAMMATION
Immunohistochemistry was performed on formalin- 
fixed paraffin-embedded sections to assess surrogate 
markers of oxidative injury and tissue inflammation.
For oxidative injury, we assessed expression of the 
following:
1. Uncoupling protein 2 (UCP-2), a mitochondrial 
inner membrane protein that uncouples the 
electron transport chain from oxidative phos-
phorylation. Elevated uncoupling protein 2 ex-
pression is associated with increased reactive 
oxygen species (ROS) production.(17,18)
2. 4-hydroxynonenal (4-HNE) as a marker of cell 
membrane phospholipid peroxidation.(19)
For the assessment of tissue inflammation, the fol-
lowing markers were analyzed:
1. Cluster of differentiation (CD)14, a lipopoly-
saccharide receptor, which is part of the toll-like 
receptor 4 signalosome. It is essential for acti-
vation of the toll-like receptor 4 via the rec-
ognition of ligands such as damage-associated 
molecular patterns (DAMPs) known to be 
up-regulated during ischemia/reperfusion 
injury.(18,19)
2. CD11b is an integrin on the surface of leukocytes; 
up-regulation on its expression indicates activa-
tion of the cells by substances including ROS.
3. Vascular cell adhesion molecule 1 (VCAM1) ex-
pression is up-regulated on vascular endothelial 
cells and Kupffer cells when activated by ROS and 
proinflammatory cytokines during ischemia/rep-
erfusion injury.(20)
All primary antibodies were detected using specific 
ImmPRESS Excel Amplified horseradish peroxidase 
Polymer Staining Kit specific to the respective mouse 
or rabbit immunoglobulin isotype. A list of primary 
antibodies and the dilution used is provided in the 
Supporting Materials.
IMMUNOHIsTOCHEMIsTRY 
QUANTITATION
Four pictures of each section excluding the edges 
were randomly selected for analysis (×400 magnifi-
cation). For UCP-2, 4-HNE, CD14, and CD11b, a 
semiquantitative scoring system, the modified im-
munoreactive score (IRS),(21) was obtained by mul-
tiplying the score for intensity (0, no color reaction; 
1, mild reaction; 2, moderate reaction; 3, intense 
reaction) and distribution (0, no positive cells; 1, 
<10% positive cells; 2, 10%-50% positive cells; 3, 
51%-80% positive cells; 4, >80% positive cells) to 
obtain a final score between 0 and 12. Change in 
the overall tissue expression of staining (ΔIRS) was 
determined by subtracting the IRS scores after 6 
hours of perfusion from the score prior to perfusion: 
Negative values indicated a decrease, and positive 
values indicated an increase in the expression of the 
staining.
VCAM1 tissue expression was assessed by image 
analysis using an established system of color differ-
entiation (ImageJ, US National Institutes of Health, 
Bethesda, MD), and the variation in the percentage of 
the positive area of staining (Δ%VCAM1) over time 
was compared between groups.
AssEssMENT OF TIssUE ATp 
CONCENTRATION
Quantification of ATP levels was done by homoge-
nization of liver tissue with the concentration de-
termined using the ATP Bioluminescent Assay kit 
(FLAA, Sigma-Aldrich Inc., St. Louis, MO). More 
details are provided in the Supporting Materials.
sTATIsTICAL ANALYsIs
Continuous variables were expressed as median with 
interquartile range (IQR) and categorical variables 
as absolute numbers with percentage frequencies. 
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Comparisons between groups were performed using 
Fisher’s exact test for categorical variables, Mann-
Whitney U test for independent continuous variables, 
and Wilcoxon signed rank test for repeated measure-
ments over time on the same sample. The statistical 
level of significance was set at P < 0.05. GraphPad 
Prism (version 6.04 for Windows, GraphPad Software, 
La Jolla, CA) software was used for all statistical anal-
yses and graph creation.
Results
DONOR DEMOGRApHICs 
AND DIsCARDED LIvER 
CHARACTERIsTICs
Seven (70%) livers were from donation after circula-
tory death (DCD). The median donor age of the entire 
cohort was 52 years (IQR, 38-54 years), and the body 
mass index was 25 kg/m2 (21-31 kg/m2). Median cold 
ischemia time (CIT) was 510 minutes (446-682 min-
utes) for DCD, and 491 minutes (454-586 minutes) for 
donation after brain death (DBD). The median donor 
risk index (DRI) was 2.2 (1.9-2.6). There were no sig-
nificant differences in donor demographics between 
the groups as shown in Table 1, and they had similar 
median DRI (NMP versus HOPE + NMP; 2.4 versus 
2.5; P = 0.78). There was a trend toward NMP livers 
having shorter SCS preservation times for DCD (449 
versus 682 minutes; P = 0.09). The detailed donor and 
liver data are presented in Tables 1 and 2.
vAsCULAR FLOWs
Portal flow patterns and end-perfusion volumes differed 
between the groups. During the initial 60 minutes of the 
NMP group perfusion, the livers’ portal flow rate in-
creased rapidly and plateaued after 180 minutes. For the 
HOPE + NMP group, steady low-volume flow rates ap-
proximating 300 mL/minute were achieved during the 
HOPE phase. The flow rate subsequently increased for 
the first 2 hours of rewarming during the NMP phase. 
The median flow rates in the HOPE + NMP group ex-
ceeded the NMP group after 210 minutes and continued 
to increase until the end of the perfusion (1300 versus 
1930 mL/minute; P = 0.03). In contrast, the arterial 
flows in the NMP livers increased more rapidly during 
the rewarming phase and remained higher throughout 
the perfusion (365 versus 732 mL/minute; P = 0.09), 
while the vascular resistance patterns and levels were sim-
ilar. The detailed data are presented in Fig. 2 and Table 1.
MITOCHONDRIAL FUNCTION 
AND OXYGEN CONsUMpTION
During the HOPE phase, livers demonstrated a decrease 
in the oxygen uptake rate and CO2 release in the perfu-
sate. The oxygen uptake during the HOPE phase peaked 
within the initial 30 minutes (0.009 [0.005-0.010] kPa/g 
liver/L perfusate) and then declined steadily (0.006 
[0.001-0.007] kPa/g liver/L perfusate) until the end of 
the 2-hour perfusion (P = 0.04). There was a concom-
itant decrease in the median PCO2 dissolved in the 
perfusate from time 0 to 2 hours of hypothermic perfu-
sion (1.3 [1.2-1.9] to 0.7 [0.6-0.8] kPa); P = 0.04). This 
change in mitochondrial respiration was associated with 
a median 1.8-fold (range, 1.3-3.9-fold) increase in tissue 
ATP levels.
The oxygen consumption in the NMP group increased 
sharply within the initial 60 minutes with distinct pat-
terns in viable compared with nonviable groups (Fig. 
2). In the HOPE + NMP livers, oxygen consumption 
increased slower during the normothermic phase and was 
maximal after 2 hours. At the end of the perfusion, the 
oxygen consumption in viable NMP livers was similar to 
livers that had HOPE (P = 0.19).
Both groups had similar ATP stores at the end of 
the 6 hours of perfusion (P = 0.31). However, there 
was a significant difference in the incremental rate 
between viable and nonviable livers in the NMP group 
(NMP viable 2.5-fold [2.4-10.9-fold]; NMP nonvia-
ble 1.1-fold [1.1-1.2-fold]; HOPE + NMP 2.7-fold 
[2.0-6.7-fold]; P = 0.05). Data are shown in Fig. 2.
LIvER FUNCTION AssEssMENT
The lactate levels and clearance dynamics differed 
between the groups. In the NMP group, lactate 
levels peaked after 60 minutes, reached the viabil-
ity criteria within 150 minutes, and subsequently 
remained low. In the HOPE + NMP livers, it did 
not change through the hypothermic phase, and it 
slowly increased in the rewarming phase with a sub-
sequent rapid clearance just after 2 hours of NMP. 
The end-perfusion lactate levels were similar in vi-
able livers from the NMP group and the HOPE + 
NMP group (1.6 versus 0.8 mmol/L; P = 0.17). In 
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the nonviable livers, lactate levels peaked after 60 
minutes with minimum levels achieved by the end 
of the perfusion of 8.5 mmol/L. A total of 3 (60%) 
livers in the NMP group and 5 (100%) in the HOPE 
+ NMP were deemed viable (P = 0.22). Details of 
the achievement of viability parameters are pre-
sented in Table 3. The 2 nonviable livers from the 
NMP group had the highest DRI, but this differ-
ence was not statistically significant (nonviable DRI 
versus viable DRI; 2.8 [2.5-3.2] versus 2.2 [1.9-2.2]; 
P = 0.13).
The glucose levels slowly increased within the 
initial 120 minutes of perfusion in the NMP group, 
followed by slow clearance until the end of the per-
fusion. In the HOPE + NMP group, they slowly 
increased through the hypothermic perfusion, fol-
lowed by a drop (related to the perfusate fluid 
replacement) with a subsequent slow increase, and 
then decreased, reaching similar figures to the NMP 
group at the end of the perfusion (26 [20-40] versus 
16 [1-17] mmol/L; P = 0.22).
Bile production at 6 hours of the perfusion was 
similar between both groups (NMP versus HOPE + 
NMP; 7.4 versus 5.2 mL/kg liver; P = 0.82). Bile pH 
(HOPE + NMP versus NMP; 7.3 [7.2-7.4] versus 7.3 
[7.2-7.5]; P > 0.99) and bile glucose (HOPE + NMP 
versus NMP; 13 [9-16] versus 21 [14-27]) were com-
parable between the groups at the end of the perfusion. 
Data are represented in Fig. 2.
HIsTOLOGICAL AssEssMENT OF 
THE LIvERs
Routine histological assessment showed no observable 
differences between the groups on the biopsy prior to 
TABLE 2. Donor Demographics, Liver Characteristics, and Machine perfusion Data
NMP (n = 5) HOPE + NMP (n = 5) P Value
Donor information
Age, years 55 (43-65) 54 (46-54) 0.84
DCD livers 4 (80) 3 (60) 0.50
Sex, male 5 (100) 2 (40) 0.17
Height, cm 184 (173-188) 179 (169-181) 0.19
Weight, kg 78 (73-85) 90 (87-106) 0.39
Body mass index, kg/m2 23 (21-27) 35 (30-37) 0.08
DRI 2.4 (1.9-2.8) 2.5 (2.2-2.7) 0.78
UK donor liver index 3.1 (1.5-15.7) 4.9 (4.0-10.6) 0.89
ET DRI 2.3 (1.9-2.9) 2.8 (2.6-2.8) 0.80
Peak ALT, IU/L 68 (44-137) 189 (37-271) 0.24
Days on ventilator 3 (1-5) 4 (2-4) 0.89
Liver characteristics
Liver weight, g 2208 (1998-2218) 1935 (1838-2060) 0.87
Donor WIT, minutes 20 (16-22) 31 (19-36) 0.42
CIT, minutes
DCD 449 (423-532) 682 (586-708) 0.09
DBD 454 (454) 586 (490-682) 0.57
Macrovesicular steatosis, % 0 (0-30) 10 (1-22) 0.98
Machine perfusion parameters
Lactate, mmol/L
Highest 10.3 (9.6-10.4) 8.9 (7.8-9.1) 0.14
Lowest 1.4 (0.6-4.1) 0.8 (0.6-1.1) 0.22
Last 1.6 (1.4-5.3) 0.8 (0.6-1.1) 0.17
Total bile production, g 18 (0-32) 16 (0-40) 0.82
NOTE: Continuous variables are presented as median and IQR; dichotomous variables are presented as absolute numbers and percent-
ages. Donor WIT was defined as the interval between the systolic blood pressure <50 mm Hg and/or arterial oxygen saturation to 
<70% to commencing the aortic cold perfusion in the donor.
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the perfusion. At the end of the perfusion, none of the 
livers presented with areas of parenchymal necrosis, 
congestion, or cytoplasmic vacuolization. The median 
large-droplet macrovesicular steatosis percentage was 
not significantly different between the groups (NMP 
versus HOPE + NMP; 0% [0%-30%] versus 10% 
[1%-22%]; P = 0.98), and only 1 liver from each group 
presented with steatohepatitis. The levels of hepatocyte 
glycogen depletion from the start to the end of the 
perfusion period were similar in both groups (NMP 
versus HOPE + NMP; 0% [–20/10] versus 10% [2/32]; 
P = 0.22) with a positive value reflecting an increase 
in the percentage of hepatocytes depleted of glycogen. 
Data are presented in Fig. 3.
IMMUNOHIsTOCHEMICAL 
AssEssMENT OF OXIDATIvE 
sTREss AND TIssUE 
INFLAMMATION
Immunohistochemical analysis showed that livers 
subjected to NMP alone expressed higher levels of 
tissue markers of oxidative injury and inflammation 
compared with those subjected to HOPE + NMP by 
the end of the perfusion run. Livers that had HOPE 
showed a significant reduction in expression of mark-
ers associated with mitochondrial ROS production 
(UCP-2; NMP ΔIRS versus HOPE + NMP ΔIRS; 
1 versus –2; P = 0.02) and oxidative stress–mediated 
FIG. 2. Perfusion parameters. Section 1: liver function assessment. (A) Perfusate lactate concentration (mmol/L) measured throughout 
the perfusion. Here, the NMP group was stratified in the viable livers (continuous red lines; 60%, n = 3) or nonviable livers (dotted 
red lines; 40%, n = 2). Blue lines represent the HOPE + NMP group livers. (B) Perfusate glucose concentration (mmol/L). Data are 
presented as median and IQR. (C) Cumulative bile production for individual livers after 4 and 6 hours of perfusion corrected for liver 
weight in kilograms. (D) Bile pH at 6 hours of perfusion was comparable between the study groups, as was (E) glucose. Section 2: 
vascular parameters of the perfusion. (F) PV f low rate in mL/minute showing that f low increased steadily in the NMP group plateauing 
after 2 hours. For HOPE + NMP, it remained low and stable during the HOPE phase, increased during the rewarming phase, and 
achieved higher rates at the end of the perfusion compared with NMP alone. (G) HA f low rate expressed in mL/minute plotted on 
the right y axis and HA vascular resistance in mm Hg/mL/minute/kg liver plotted on the left y axis. Despite similar resistances at the 
end of the perfusion, the HA f low reached higher values at the end of the perfusion in the NMP group. Section 3: HOPE phase and 
mitochondrial function. (H) Oxygen uptake during the HOPE phase of the HOPE + NMP group (ΔinflowO2-outf lowO2), expressed 
as median and IQR. (I) PCO2 (kPa) released in the perfusate decreased steadily throughout the hypothermic perfusion phase. (J) 
Tissue ATP levels (nmol/g) at time 2 hours were normalized for the concentration at time 0 and expressed as fold changes. Data are 
presented as median and minimum/maximum. Section 4: Energy status during perfusion. (K) Oxygen consumption during the NMP 
phase for both groups; NMP stratified according to viability criteria with the continuous red line representing viable and the dotted 
red line representing nonviable, respectively. Data are presented as median and IQR. Oxygen consumption increased sharply within 
the initial 60 minutes of NMP, whereas the HOPE + NMP livers presented a slower increase in oxygen consumption during the 
normothermic phase. (L) PCO2 (kPa) released in the perfusate during the NMP phase showing that figures were similar between the 
viable livers of the NMP group and the HOPE + NMP group. Nonviable livers from the NMP group presented with higher perfusate 
PCO2 levels throughout the entire duration of perfusion. (M) Tissue ATP levels (nmol/g) over 6 hours of perfusion. Figures at time 
2 hours and 6 hours were normalized for the concentration at t = 0 and expressed as a fold increase. Levels of significance: *P < 0.05 
(Wilcoxon signed rank test).
TABLE 3. viability Criteria Achievement by the Livers in Each Group
Criteria NMP (n = 5) HOPE + NMP (n = 5)
Lactate clearance (≤2.5 mmol/L) 3 (60) 5 (100)
pH >7.3 perfusate 2 (40) 2 (40)
Glucose metabolism 3 (60) 4 (80)
HA flow (>150 mL/minute) 5 (100) 5 (100)
PV flow (>500 mL/minute) 5 (100) 5 (100)
Homogeneous perfusion/soft parenchyma 5 (100) 5 (100)
Bile production 3 (60) 3 (60)
Viable liver 3 (60) 5 (100)
NOTE: Data are given as n (%).
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cellular injury (4-HNE) expression reflecting lipid 
peroxidation (NMP ΔIRS versus HOPE + NMP 
ΔIRS; 1 versus –2; P = 0.008). Both proteins were 
present predominantly in hepatocytes. Similarly, they 
showed decreased expression of CD14 at the end of the 
perfusion compared with commencement. A statisti-
cally significant opposite trend was seen for the livers 
perfused using NMP only (NMP ΔIRS versus HOPE 
FIG. 3. Liver histology before and after machine perfusion. (A) Hematoxylin-eosin and the (B) PAS staining at the beginning (t = 
0) and end of the perfusion (t = 6 hours). No observable histological differences were seen between the 2 groups prior to or at the end 
of perfusion. There was no evidence of perfusion-related ischemic coagulative necrosis developed in any liver during perfusion. (C) 
The percentage of areas of glycogen deposition (parenchymal PAS staining) from start to end of the perfusion was also similar in both 
groups.
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+ NMP ΔIRS; 3 versus –2; P = 0.008). The inten-
sity of the tissue inflammatory response was shown 
by different patterns of nonparenchymal cell staining 
for CD11b, which was present on polymorphonuclear 
leukocytes (neutrophils and monocytes/macrophages). 
There was a significant difference in its level of expres-
sion between the 2 groups throughout the perfusion 
(NMP ΔIRS versus HOPE + NMP ΔIRS; 3 versus 
–1; P = 0.02), suggesting a potential beneficial effect 
of the combined protocol. Intrahepatic endothelial 
cells play a key role in reperfusion injury by promot-
ing leukocyte adhesion and retention. To evaluate the 
(cytokine-mediated) activation of endothelial cells, the 
percentages positive areas of VCAM1 staining were 
determined. VCAM1 expression decreased over time 
in both groups, but this was more pronounced in livers 
that had undergone HOPE (NMP Δ%VCAM1 versus 
HOPE + NMP Δ%VCAM1; –0.5 versus –2.2; P = 
0.05). Data are presented in Fig. 4.
Discussion
Machine perfusion was developed to minimize 
damage during organ preservation, and early clin-
ical experience proved its superiority over SCS and 
positive impact on extended criteria liver utiliza-
tion.(8,12,13,22,23) The 2 leading perfusion strategies, 
hypothermic and normothermic technique, have 
previously been viewed as diverse, or even compet-
ing, approaches with each having advantages and 
disadvantages.(24) In the present study, we compared 
a protocol that combined the 2 methods to evaluate 
whether the combination would provide the poten-
tial benefits of both. We found that initial HOPE 
perfusion promoted recovery of mitochondrial func-
tion, increased ATP energy stores, and lowered tis-
sue injury during subsequent NMP. Normothermic 
perfusion allowing viability assessment is seen by 
our group as an essential aspect of patient safety for 
transplantation of the highest-risk and/or currently 
unused livers. The combination of HOPE with 
NMP translated into the increased rate of functional 
recovery of livers pretreated with HOPE compared 
with livers subjected to NMP alone.
Our team became an early adopter of the NMP 
technique, and we observed that a proportion of livers 
failed to recover their function.(12) Those poor-quality 
organs, often exposed to prolonged CITs, were unable 
to maintain vascular flows, clear lactate, or produce any 
bile. With the mounting evidence of the protective 
mechanism of HOPE, we designed the combined 
perfusion to assess if this intervention would yield a 
superior functional recovery for the highest-risk dis-
carded livers.(7,22,24,25) Our key objective in designing 
this experiment was to imitate the real-life situation 
where clinical decisions are required regarding trans-
plantability of a clearly suboptimal liver upon its arrival 
to the transplant center.
Although the use of HOPE with subsequent NMP 
was reported by the Groningen group previously, their 
experiment was aimed at assessing benefit of HOPE 
compared with SCS and used the NMP phase to sim-
ulate in vivo reperfusion.(26) In this scenario, the over-
all perfusion time on the device at the point of the 
functional assessment was beyond the certified scope 
of 6-hour use, limiting its value for translation toward 
clinical adoption.(26,27)
Our study represents a novel approach and shows 
unique data, as it assesses the viability of human 
donor livers using clinically validated criteria.(12,28,29) 
Previous rodent models of ECD livers showed that a 
short period of HOPE was able to promote recovery of 
mitochondrial function, optimizing oxygen utilization 
and recovering cellular ATP energy stores.(25,30) HOPE 
was suggested to promote metabolism of the succinate 
accumulated during the ischemic period under hypo-
thermic conditions, subsequently diminishing the 
reversal flow of electrons from the mitochondria and 
the production of ROS during the rewarming.(31)
Although there has been extensive mechanistic 
research using animal models showing a down-regu-
lation in the tissue inflammatory responses, including 
activation of endothelial and resident immune cells 
of the liver, the evidence from human livers, espe-
cially those from the highest-risk donor pool, is very 
scarce.(18,24) In order to assess the extent of the injury 
developed during rewarming on the machine, we ana-
lyzed numerous markers of nonparenchymal cell acti-
vation. In accordance with previous observations, we 
confirmed the putative benefits of HOPE, in compar-
ison to negligible changes or even an up-regulation of 
detrimental processes observed during NMP perfusion 
alone.(24,31) We have shown changes in the mitochon-
drial respiratory rate during the HOPE phase of the 
combined perfusion group that correlated with lower 
activation of the inflammatory cascade and oxidative 
injury at the end of 6 hours of machine perfusion in 
comparison with NMP alone. Replacement of the 
perfusate, which may reduce toxic metabolites and 
detritus accumulated during SCS, and recirculating 
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FIG. 4. Immunohistochemical analysis for markers of ROS-mediated damage and tissue inf lammation. The upper row of each panel 
shows representative images for the HOPE + NMP group, and the lower images show representative images for the NMP group prior 
to and at the end of perfusion (t = 0 and t = 6 hours). (A) There was a consistent reduction in expression of markers for oxidative injury 
in the HOPE + NMP group as ref lected by the IRS. In contrast, an opposite trend was seen for the NMP livers over the course of the 
perfusion. (B) Markers indicative of activation of the inf lammatory cascade also showed reduced expression by the end of perfusion in 
the HOPE + NMP group. Although VCAM1 expression decreased in both groups, it trended toward being more pronounced in livers 
that had undergone HOPE + NMP. Bold outside border white squares at the bottom of figures represents 50 µm, and no border white 
squares represent 100-µm scaling. Levels of significance: *P < 0.05 (Wilcoxon signed rank test).
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perfusate may also further enhance reduction of the 
tissue inflammatory response and injury in the HOPE 
+ NMP group. The lack of the liver flush following the 
HOPE phase might alter the perfusion fluid constitu-
tion for the normothermic perfusion in the HOPE + 
NMP group. However, analyses of these minimal dif-
ferences between the groups were beyond the scope of 
the present study.(32,33)
NMP provides a near-physiological environment 
for the liver by supplying oxygen and nutrients at 
normothermic condition, enabling the organ func-
tional assessment. Our previous work on end-ischemic 
NMP of declined human livers allowed us to define 
the viability criteria employed for transplantation of 
discarded human livers.(12,28) Setting the achievement 
of viability criteria already used for clinical transplan-
tation as an endpoint is an important strength of this 
study. However, we appreciate that a consensus does 
not yet exist regarding optimal parameters for organ 
viability assessment during NMP.(17,26,34,35) Lactate 
clearance to levels lower than 2.5 mmol/L is a prin-
cipal parameter for viability criteria used at our unit. 
Although this marker is seen in our clinical practice 
as a highly sensitive and specific parameter to predict 
early graft failure due to primary nonfunction, Watson 
et al. recently advocated transaminase levels in the per-
fusate and bile quality assessment, by the pH and glu-
cose content, to be superior in terms of predicting late 
graft loss due to biliary complications.(35) This is a per-
tinent point because the previous clinical studies have 
demonstrated the key advantage of HOPE perfusion 
being preventative of nonanastomotic biliary stric-
tures in DCD livers, and these organs might benefit 
most from the combined protocol.(7,32) The presented 
data showed improved viability also in DBD livers. 
Despite the limited number of perfusions included in 
our study, all assays from the HOPE + NMP group 
consistently showed cytoprotective effects and superior 
parameters, including clinical viability criteria (a dia-
grammatic summary is presented in Fig. 5). This was 
demonstrated by all HOPE + NMP organs achieving 
the viability criteria, whereas 40% (2/5) of the organs 
perfused by NMP alone failed to recover enough func-
tion to be deemed transplantable.
The use of an acellular hemoglobin-based oxygen 
carrier was shown by our group and others to be a suit-
able alternative to the use of packed red cells in the 
context of NMP.(16,36) An acellular oxygen carrier–
based fluid could be potentially used throughout the 
whole perfusion, avoiding any change of perfusate. 
Nevertheless, in logistic terms, the disconnection of 
the liver from the perfusion circuit for approximately 
20 minutes, which is necessary to exchange the device 
perfusate, seemingly did not cause any measurable 
harm to the organs temporarily placed on ice. HOPE 
perfusion via PV only was previously shown to provide 
sufficient oxygenation for the entire liver, including the 
extrahepatic biliary tree, without any need for manipu-
lation of the HA at this stage.(7,24,37)
The feasibility of combining variant perfusion 
techniques has been suggested before, though the 
advantages, caveats, and logistics aspects of different 
combinations are yet to be seen.(38) The current study 
is the first to show a combined protocol of HOPE + 
NMP that might be easily adopted to clinical practice. 
A short-term HOPE phase optimizes mitochondrial 
oxidative function, decreasing tissue oxidative injury 
and the downstream activation of the inflammatory 
cascade during reperfusion. Thus, HOPE mitigates 
ischaemia/reperfusion injury during NMP. Those 
factors together might be essential to minimize any 
damage and improve functional recovery in the high-
est-risk ECD livers damaged by cold ischemia during 
the SCS prior to the end-ischemic machine perfusion. 
This approach differs from NMP preservation when 
the organs are exposed only to a very short period of 
ischemia.(23) The Liver Assist device enables variation 
of perfusion strategies in temperatures ranging from 
10°C to 37°C within the device-certified 6-hour time-
frame. The presented study used 2 hours of HOPE 
and 4 hours of NMP, durations previously recom-
mended by other groups, allowing for the use of a sin-
gle perfusion kit and rendering the combined perfusion 
cost-effective.(23,26)
The present study has some caveats. It is not a 
transplant model because this would not be clinically 
possible in the United Kingdom at this early investi-
gative stage. Although the reperfusion injury could be 
simulated by a subsequent NMP with whole blood, we 
opted to study the organ functional recovery only, and 
we have applied our current viability criteria to define 
its potential transplantability. Those criteria have been 
used by our team in clinical trials to safely transplant 
discarded human livers, allowing us to compare the 
findings and predict transplantability and clinical rele-
vance of our preclinical proof of concept studies.(12,29) 
The use of discarded human livers for research confers 
the advantage of eliminating between-species variabil-
ity, which is a limitation for animal models where the 
extrapolation of results to humans is questionable. The 
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FIG. 5. Diagrammatic summary of the findings and proposal for the use of a combined protocol of ex situ machine perfusion 
encompassing HOPE and NMP for the recovery of ECD livers. The top panel of the diagram illustrates current clinical practice for 
standard or low-risk extended criteria organs, which are preserved using the traditional SCS. The middle panel shows the potentially 
beneficial effects of each machine perfusion protocol. HOPE perfusion does not permit objective organ viability assessment, which 
limits its potential use for high-risk ECD livers. NMP potentially allows viability assessment prior to transplantation, making this 
option extremely valuable for high-risk ECD livers. In fact, a significant proportion of these high-risk organs do not achieve our 
viability criteria when submitted to NMP alone. The bottom panel summarizes the outcome and possible mechanistic benefits of the 
combined protocol of HOPE + NMP. This newly developed protocol was shown to derive individual benefits of both techniques. This 
is ref lected by demonstrating a higher rescue of high-risk ECD livers in the HOPE + NMP group than NMP alone.
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scarcity and intrinsic heterogeneity among discarded 
human livers, however, makes it difficult to achieve 
perfectly matched study groups.
Using an acellular oxygen carrier fluid also precludes 
any direct comparison of our data with frequently 
published machine perfusion studies’ endpoints, 
including perfusate transaminases.(23,34,35) The free 
hemoglobin concentration in the Hemopure-based 
perfusate exceeded the maximum hemolytic index 
tolerance for our hospital clinical laboratory assess-
ment, and we were unable to measure those subse-
quently by alternative methods from rethawed frozen 
samples. As a similar perfusion fluid has already been 
used for clinical perfusions, we expect that it might 
be soon widely adopted and our results validated by 
others.
In conclusion, this proof of concept study demon-
strated that the combination of sequential HOPE 
and NMP is not only feasible, but that it may poten-
tially improve the functional recovery of high-risk 
ECD livers compared with NMP alone. Although 
we do not suggest that this is an optimized proto-
col, this novel approach might be particularly bene-
ficial for DCD organs. Further studies are needed to 
explore whether the combined protocol confers other 
benefits, such as the reduced biliary complications of 
HOPE or the safety of prolonged perfusions of NMP.
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